{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T09:16:16Z","timestamp":1760346976436,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arbeitsgemeinschaft Internistische Onkologie (AIO), CUP working group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with carcinoma of unknown primary (CUP) have a dismal prognosis, even when treated with multi-agent chemotherapy. We hypothesised that adding the epidermal growth-factor receptor (EGFR) inhibitor cetuximab to standard first-line chemotherapy with paclitaxel and carboplatin would improve PFS and RR in unfavourable CUP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This open-labelled, multicentre Phase 2 study included patients with unfavourable, untreated adeno- or undifferentiated CUP. Patients were randomised to receive either paclitaxel\/carboplatin (group A) or paclitaxel\/carboplatin plus cetuximab (group B) every 3 weeks for a maximum of 6 cycles followed by cetuximab maintenance in group B. The primary endpoint was PFS in the two groups. Secondary endpoints were RR, toxicity and overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One-hundred-and-fifty patients were randomised (group A\u2009=\u200972, group B\u2009=\u200978). The median PFS and OS for all patients were 3.8 and 8.1 months (95% confidence interval (CI): 2.9\u20134.8 and 6.8\u20139.5). There was no significant difference in PFS (3.7 vs 4.6 months, HR 0.98) or OS (8.1 vs 7.4, HR 1.1) between the two treatment groups. Response rate tended to be better for chemotherapy plus cetuximab compared to chemotherapy alone (22% vs 15%). Adverse events grade \u22653 were comparable between the two groups, except for significantly increased skin toxicity in the cetuximab arm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cetuximab plus paclitaxel\/carboplatin did not improve PFS, OS and RR in metastatic CUP compared to paclitaxel\/carboplatin alone. Addition of cetuximab resulted in additional skin toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial registration<\/jats:title>\n                <jats:p>The study was registered at clinicaltrials.gov as NCT00894569.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-01141-8","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T02:03:17Z","timestamp":1606269797000},"page":"721-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP"],"prefix":"10.1038","volume":"124","author":[{"name":"Arbeitsgemeinschaft Internistische Onkologie (AIO) - CUP Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Folprecht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolin","family":"Trautmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerdt","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Kretzschmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus-Henning","family":"K\u00f6hne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-7687","authenticated-orcid":false,"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Sch\u00fctte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"L\u00f6ffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"1141_CR1","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canep.2019.06.006","volume":"61","author":"E Rassy","year":"2019","unstructured":"Rassy, E. & Pavlidis, N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol. 61, 139\u2013141 (2019).","journal-title":"Cancer Epidemiol."},{"key":"1141_CR2","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis, N. & Pentheroudakis, G. Cancer of unknown primary site. Lancet. 379, 1428\u20131435 (2012).","journal-title":"Lancet."},{"key":"1141_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0332-2","volume":"120","author":"A-M Conway","year":"2019","unstructured":"Conway, A.-M., Mitchell, C., Kilgour, E., Brady, G., Dive, C. & Cook, N. Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the \u2018U\u2019 out of \u2018CUP.\u2019. Br. J. Cancer 120, 141\u2013153 (2019).","journal-title":"Br. J. Cancer"},{"key":"1141_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3083-1","volume":"17","author":"W Jones","year":"2017","unstructured":"Jones, W., Allardice, G., Scott, I., Oien, K., Brewster, D. & Morrison, D. S. Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer 17, 85 (2017).","journal-title":"BMC Cancer"},{"key":"1141_CR5","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","volume":"28","author":"AM Varghese","year":"2017","unstructured":"Varghese, A. M., Arora, A., Capanu, M., Camacho, N., Won, H. H., Zehir, A. et al. Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Ann. Oncol. 28, 3015\u20133021 (2017).","journal-title":"Ann. Oncol."},{"key":"1141_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute. J. Clin. Oncol. 31, 217\u2013223 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR7","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2000.18.17.3101","volume":"18","author":"E Briasoulis","year":"2000","unstructured":"Briasoulis, E., Kalofonos, H., Bafaloukos, D., Samantas, E., Fountzilas, G., Xiros, N. et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a Phase II Hellenic Cooperative Oncology Group Study. J. Clin. Oncol. 18, 3101\u20133107 (2000).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/EdBook_AM.2013.33.175","volume":"33","author":"FA Greco","year":"2013","unstructured":"Greco, F. A. Cancer of unknown primary site: improved patient management with molecular and immunohistochemical diagnosis. Am. Soc. Clin. Oncol. Educ. B. 33, 175\u2013181 (2013).","journal-title":"Am. Soc. Clin. Oncol. Educ. B."},{"key":"1141_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/sj.bjc.6604818","volume":"100","author":"G Huebner","year":"2009","unstructured":"Huebner, G., Link, H., Kohne, C. H., Stahl, M., Kretzschmar, A., Steinbach, S. et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br. J. Cancer 100, 44\u201349 (2009).","journal-title":"Br. J. Cancer"},{"key":"1141_CR10","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdv543","volume":"27","author":"HH Yoon","year":"2016","unstructured":"Yoon, H. H., Foster, N. R., Meyers, J. P., Steen, P. D., Visscher, D. W., Pillai, R. et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann. Oncol. 27, 339\u2013344 (2016).","journal-title":"Ann. Oncol."},{"key":"1141_CR11","doi-asserted-by":"crossref","unstructured":"Hainsworth J. D., Daugaard G., Lesimple T., H\u00fcbner G., Greco F. A., Stahl M. J. et al. Paclitaxel\/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial. Cancer 121, 1654\u20131661 (2015).","DOI":"10.1002\/cncr.29229"},{"key":"1141_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1634\/theoncologist.2009-0112","volume":"14","author":"JD Hainsworth","year":"2009","unstructured":"Hainsworth, J. D., Spigel, D. R., Thompson, D. S., Murphy, P. B., Lane, C. M., Waterhouse, D. M. et al. Paclitaxel\/carboplatin plus bevacizumab\/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 14, 1189\u20131197 (2009).","journal-title":"Oncologist"},{"key":"1141_CR13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359, 1116\u20131127 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","volume":"27","author":"C Bokemeyer","year":"2009","unstructured":"Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., De Braud, F. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663\u2013671 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E., K\u00f6hne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR16","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"F Ciardiello","year":"2008","unstructured":"Ciardiello, F. & Tortora, G. EGFR Antagonists in cancer treatment. N. Engl. J. Med. 358, 1160\u20131174 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR17","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.ejca.2007.06.023","volume":"43","author":"G Pentheroudakis","year":"2007","unstructured":"Pentheroudakis, G., Golfinopoulos, V. & Pavlidis, N. Switching benchmarks in cancer of unknown primary: From autopsy to microarray. Eur. J. Cancer 43, 2026\u20132036 (2007).","journal-title":"Eur. J. Cancer"},{"key":"1141_CR18","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi, K., Greco, F. A., Pavlidis, N., Daugaard, G., Oien, K. & Pentheroudakis, G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, v133\u2013v138 (2015).","journal-title":"Ann. Oncol."},{"key":"1141_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205\u2013216 (2000).","journal-title":"J. Natl. Cancer Inst."},{"key":"1141_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"J-Y Douillard","year":"2013","unstructured":"Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023\u20131034 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1141_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","volume":"17","author":"S Moran","year":"2016","unstructured":"Moran, S., Mart\u00ednez-Card\u00fas, A., Sayols, S., Musul\u00e9n, E., Bala\u00f1\u00e1, C., Estival-Gonzalez, A. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 17, 1386\u20131395 (2016).","journal-title":"Lancet Oncol."},{"key":"1141_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.18.00771","volume":"37","author":"H Hayashi","year":"2019","unstructured":"Hayashi, H., Kurata, T., Takiguchi, Y., Arai, M., Takeda, K., Akiyoshi, K. et al. Randomized Phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J. Clin. Oncol. 37, 570\u2013579 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1141_CR23","doi-asserted-by":"crossref","unstructured":"Fizazi K., Maillard A., Penel N. et al. A phase 3 trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Present ESMO Congr 2019, Barcelona Spain; LBA15_PR.","DOI":"10.1093\/annonc\/mdz394"},{"key":"1141_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2019.12.016","volume":"127","author":"E Rassy","year":"2020","unstructured":"Rassy, E., Bakouny, Z., Choueiri, T. K., Van Allen, E. M., Fizazi, K., Greco, F. A. et al. The role of site-specific therapy for cancers of unknown of primary: a meta-analysis. Eur. J. Cancer 127, 118\u2013122 (2020).","journal-title":"Eur. J. Cancer"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01141-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-01141-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:55Z","timestamp":1684616815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-01141-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,16]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-01141-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"25 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The legal sponsor of the study was the University of Heidelberg, Germany. The study protocol was approved by the ethics committee of the University of Heidelberg, Germany (leading ethics committee in Germany for this trial, reference number AFmu-408\/2008) and by the responsible local ethics committees of all participating centres (ethics committees of the Technische Universit\u00e4t Dresden, Medizinische Hochschule Hannover, Medizinische Fakult\u00e4t f\u00fcr Klinische Medizin Mannheim der Ruprecht-Karls-Universit\u00e4t Heidelberg, \u00c4rztekammer Schleswig-Holstein, \u00c4rztekammer Niedersachsen, Land Berlin am Landesamt f\u00fcr Gesundheit und Soziales Berlin, Landes\u00e4rztekammer Rheinland-Pfalz, Universit\u00e4t Ulm, \u00c4rztekammer Nordrhein, Medizinische Fakult\u00e4t der Universit\u00e4t D\u00fcsseldorf-Essen, Universit\u00e4t Regensburg, \u00c4rztekammer Hamburg, \u00c4rztekammer Westfalen-Lippe und der Medizinischen Fakult\u00e4t der Westf\u00e4lischen Wilhelms-Universit\u00e4t M\u00fcnster and Medizinische Fakult\u00e4t der Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen\u2014all Germany). The trial was performed in accordance with the Declaration of Helsinki. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Access to the anonymised dataset can be requested from the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"G.F. received a study grant by Merck and honoraria for lectures and advisory board meetings from Merck, Roche, Amgen, Lilly, Sanofi-Aventis, Servier, Bayer, BMS and MSD. K.T. received honoraria for lectures and advisory board meetings from BMS, Celgene, Takeda, GSK, Servier and Janssen-Cilag. A.S. received research grants from Merck, BMS, Roche, Sanofi, Servier, German Cancer Aid and Federal Joint Committee, and honoraria for lectures and advisory board meetings by Merck, Roche, Amgen, Lilly, Sanofi-Aventis, Servier, Bayer, BMS, MSD and Sirtex. G.H. received honoraria for lectures and advisory board meetings by BMS, Sanofi-Aventis, Novartis, Roche and Boehringer Ingelheim. M.S. received honoraria for lectures from Merck and Amgen. SK received financial support for conduction of clinical trials by Merck, BMS; Roche, Celgene and Lilly and received honoraria for lectures and advisory board meetings from Merck, Roche, Amgen, Lilly, Sanofi-Aventis, Servier, Bayer, BMS, MSD and GSK. A.K.R.E. received honoraria for lectures and advisory board meetings or travel support for medical conference attendance by Merck, Roche, Amgen, Sanofi-Aventis, Servier, BMS and MSD. C.H.K. received a study grant and honoraria for lectures and advisory board meetings from Merck, Roche, Amgen, Lilly, Sanofi-Aventis, Servier, Bayer, BMS, MSD and Novartis. V.G. acted as an advisor for BMS, MSD, Merck Serono, AstraZeneca, Novartis, Pfizer, Ipsen, Cerulean, EUSA-Pharm., Roche and Nanobiotix and received compensation for lectures from BMS, MSD, Merck Serono, AstraZeneca, Novartis, Pfizer, Ipsen, Eisai, Roche, PharmaMar, Lilly, Janssen-Cliag and Exelexis. He received research grants from AstraZeneca, BMS, MSD, Pfizer and Ipsen. C.B. received honoraria for lectures and advisory board meetings from Lilly, Merck, Sanofi, Roche Mundipharma, Bayer, Hexal, GSO, BMS, Servier, Pfizer and AstraZeneca. A.K.R.\u00c4. received research support by Bayer and Merck Serono, study grants by Merck and BMS and honoraria for lectures and advisory board meetings, as well as reimbursement for study-related travels by Roche and Daiichi-Sankyo. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was supported by the German Arbeitsgemeinschaft f\u00fcr Internistische Onkologie (AIO), CUP working group and by an unrestricted grant and provision of cetuximab by Merck-Serono GmbH, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Open Access funding enabled and organized by Projekt DEAL.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}